Altre lingue Lipidor AB

Azioni

LIPI

SE0012558617

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 11/07/2024			Variaz. 5gg	Var. 1 gen.
0,047 ^SEK	-6,00%		+8,80%	-90,67%

22/05	Lipidor AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
22/04	Lipidor AB (publ) rinvia la pubblicazione della Relazione annuale per il 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue	01/07
Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants	25/06
Lipidor announces final outcome in the rights issue	13/06
Lipidor announces preliminary outcome in the rights issue	12/06
Last day of trading in unit rights in Lipidor's rights issue	07/06
Bulletin from the Annual General Meeting of Lipidor AB (publ)	05/06
Lipidor invites to digital presentations with Q&A	29/05
Today the subscription period in Lipidor's rights issue begins	29/05
Lipidor publishes prospectus due to upcoming rights issue of units	24/05
Lipidor AB (publ) publishes interim report for Q1 2024	22/05
Lipidor AB Reports Earnings Results for the First Quarter Ended March 31, 2024	22/05
Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)	21/05
Lipidor AB (publ) publishes annual report for 2023	15/05
NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)	07/05
Lipidor AB announces new date for publication of Annual Report 2023	22/04
Lipidor AB Postpones the Publication of Annual Report for 2023	22/04
NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)	10/04
Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study	10/04
Lipidor completes planned divestment of shares in Emollivet	26/03
Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2	21/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Lipidor AB

Azioni

LIPI

SE0012558617

Altre lingue

Filtri